 |
인쇄하기
취소
|
ViroMed to conduct VM202-PAD Phase 2 clinical trial in China
VM202 Phase 2 clinical trials for Peripheral Artery Disease (PAD) will commence in China, projected to be the third largest pharmaceutical market in the world by 2013.
Unlike other treatments, VM202-PAD is designed to treat the fundamental causes of PAD. It represents a huge unmet need, as millions of people with PAD experience debilitating pain every day. ViroMed is dedicated to bringing VM...
Unlike other treatments, VM202-PAD is designed to treat the fundamental causes of PAD. It represents a huge unmet need, as millions of people with PAD experience debilitating pain every day. ViroMed is dedicated to bringing VM...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.